Clinical trial NCT01718899: Phase 1/2a Study of Cancer Vaccine to Treat Smoldering Multiple Myeloma
Official title: A Phase 1/2a Dose Escalation Study of PVX-410, a Multi-Peptide Cancer Vaccine, in Patients With Smoldering Multiple Myeloma
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE1
Conditions: Smoldering Multiple Myeloma
Lead sponsor: OncoPep, Inc.
Sponsor class: INDUSTRY
First posted: 2012-10-31
Enrollment: 22
Sex: ALL
Minimum age (years): 18
Maximum age (years): 95
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NON_RANDOMIZED
Intervention model: SINGLE_GROUP
Primary purpose: TREATMENT

Brief summary: The purpose of this study is to determine the safety and tolerability of PVX-410, (a cancer vaccine), treatment regimen for patients with smoldering multiple myeloma as a single agent and in combination with lenalidomide.

Detailed description: This is a dose escalation, phase 1/2a study to assess the safety and tolerability of PVX-410, (a multi-peptide cancer vaccine), treatment regimen in patients with smoldering multiple myeloma as a single agent and in combination with lenalidomide.. Approximately 22 patients will receive six (6) bi-weekly, subcutaneous injections of PVX-410 for a total of twelve (12) weeks of treatment. Safety will be monitored throughout the study. Tolerability, immunogenicity and clinical response will also be measured as described in the protocol.

Eligibility criteria: * Patient has confirmed clinical diagnosis of SMM according to a definition derived from the International Myeloma Working Group (IMWG) definition: serum M-protein ≥3 g/dL or bone marrow clonal plasma cells (BMPC) greater than or equal to 10%, or both, along with normal organ and marrow function (CRAB) within 4 weeks before baseline.
* C: Absence of hypercalcemia, evidenced by a calcium \<10.5 mg/dL.
* R: Absence of renal failure, evidenced by a creatinine \<2.0 mg/dL or calculated creatinine clearance (using the Modification of Diet in Renal Disease \[MDRD\] formula) \>50 mL/min.
* A: Absence of anemia, evidenced by a hemoglobin \>10 g/dL.
* B: Absence of lytic bone lesions on standard skeletal survey.
* Patient is at higher than average risk of progression to active MM, defined as having 2 or more of the following features:
* Serum monoclonal (M)-protein ≥3 g/dL.
* BMPC greater than or equal to 10%.
* Abnormal serum free light chain (FLC) ratio (0.26-1.65).
* Patient has a life expectancy of greater than 6 months
* Patient is human leukocyte antigen (HLA)-A2 positive.
* Patient has an Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1.
* Patient has adequate bone marrow function, evidenced by a platelet count ≥75×109/L and an absolute neutrophil count (ANC) ≥1.0×109/L within 2 weeks before baseline.
* Patient has adequate hepatic function, evidenced by a bilirubin ≤2.0 mg/dL and an alanine transaminase (ALT), and aspartate transaminase (AST) ≤2.5× the upper limit of normal (ULN) within 2 weeks before baseline.
* If of child-bearing potential, patient agrees to use adequate birth control measures during study participation.
* If a female of child-bearing potential, patient has negative urine pregnancy test results within 2 weeks before baseline and is not lactating.
* Patient (or his or her legally accepted representative) has provided written informed consent to participate in the study.

Exclusion Criteria:

* Patient has symptomatic multiple myeloma, as defined by any of the following:
* Lytic lesions or pathologic fractures.
* Anemia (hemoglobin \<10 g/dL).
* Hypercalcemia (corrected serum calcium \>11.5 mg/dL).
* Renal insufficiency (creatinine \>2 mg/dL).
* Other: symptomatic hyperviscosity, amyloidosis.
* Patient has abnormal cardiac status, evidenced by any of the following:
* New York Heart Association (NYHA) stage III or IV congestive heart failure (CHF).
* Myocardial infarction within the previous 6 months.
* Symptomatic cardiac arrhythmia requiring treatment or persisting despite treatment.
* Patient is receiving any other investigational agent.
* Patient has a current active infectious disease or positive serology for human immunodeficiency virus (HIV), hepatitis C virus (HCV), or hepatitis B virus (HBV).
* Patient has a history of or current auto-immune disease.
* Patient has been vaccinated with live attenuated vaccines within 4 weeks before study vaccination.

Primary outcomes:
measure: All adverse events will be recorded.
timeFrame: Throughout treatment phase (3 months) and follow up period (12 months)
Secondary outcomes:
measure: Immune response to the vaccine will be measured
timeFrame: Designated timepoints during the treatment phase (3 months) and follow up phase (12 months)
Other outcomes:
measure: Clinical Response will be measured.
timeFrame: Designated timepoints during the treatment phase (3 months) and follow up phase (12 months)
Locations:
city: Atlanta
country: United States
facility: Winship Cancer Institute, Emory University
state: Georgia
city: Niles
country: United States
facility: Illinois Cancer Specialists
state: Illinois
city: Boston
country: United States
facility: Beth Israel Deaconess Medical Center
state: Massachusetts
city: Boston
country: United States
facility: Dana Farber Cancer Institute
state: Massachusetts
city: Boston
country: United States
facility: Massachusetts General Hospital
state: Massachusetts
city: Houston
country: United States
facility: University of Texas, MD Anderson Cancer Center
state: Texas
Study officials:
affiliation: Massachusetts General Hospital
name: Noopur Raje, MD
role: PRINCIPAL_INVESTIGATOR
affiliation: M.D. Anderson Cancer Center
name: Michael Wang, MD
role: PRINCIPAL_INVESTIGATOR
affiliation: Emory University
name: Ajay Nooka, MD
role: PRINCIPAL_INVESTIGATOR
References:
citation: Nooka AK, Wang ML, Yee AJ, Kaufman JL, Bae J, Peterkin D, Richardson PG, Raje NS. Assessment of Safety and Immunogenicity of PVX-410 Vaccine With or Without Lenalidomide in Patients With Smoldering Multiple Myeloma: A Nonrandomized Clinical Trial. JAMA Oncol. 2018 Dec 1;4(12):e183267. doi: 10.1001/jamaoncol.2018.3267. Epub 2018 Dec 13.